Inclusion Criteria:

          1. Signed written informed consent

          2. Newly diagnosed stage III or IVA squamous-cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx

          3. Female or male patients, aged at least 18 years

          4. Patients in Complete Response after treatment of their primary tumor.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

          6. Adequate hematological, hepatic and renal functions

        Exclusion Criteria:

          1. Patients with carcinoma of the nasopharynx, squamous cell-carcinoma of unknown
             primary, squamous cell carcinoma that originates from the skin and salivary gland or
             paranasal sinus, non-squamous histologies.

          2. Prior exposure to cancer immunotherapy including anti-cancer vaccines, any antibody
             targeting T-cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA4
             antibodies.

          3. Other active malignancy requiring concurrent systemic intervention.

          4. Patients with previous malignancies other than the target malignancy to be
             investigated in this trial

          5. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known
             Acquired Immune Deficiency Syndrome (AIDS)

          6. Clinical or laboratory history or evidence of Hepatitis C Virus (HCV) or Hepatitis B
             Virus (HBV) indicating acute or chronic infection

          7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (> 10 mIU/mL)

          8. Treatment with another investigational agent within 30 days prior to TG4050 treatment
             initiation

          9. Uncontrolled intercurrent illness